BDC-4182: A Claudin 18.2-Targeting ISAC with Significantly Enhanced Immune Activity and Efficacy in Low Antigen Density Models

  • Integrating saRNA and siRNA payloads into antibody conjugates
  • Managing immunogenicity and safety considerations
  • Identifying the next wave of oligonucleotide drug conjugate candidates